- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04258059
Wells and Enteric Disease Transmission Trial (WET - Trial)
July 29, 2022 updated by: Heather Murphy, Temple University
Wells and Enteric Disease Transmission - A Randomized Controlled Trial (WET- Trial)
Approximately 40 million people in the US are served by private wells, many of which are untreated.
The investigators estimate that 1.29 million cases of gastrointestinal illness (GI) per year are attributed to consuming water from untreated private wells in the US.
These cases of GI can cause a significant burden in terms of health care costs and lost work/school days, as well as increased risk to developing longer term health complications.
This impact is magnified when accounting for vulnerable populations such as children under the age of 5, the elderly and the immunocompromised.
The investigators are preparing to conduct the first household randomized controlled trial (RCT) to investigate whether consuming well water treated by ultraviolet light (UV) compared to consuming untreated private well water decreases the incidence of self-reported gastrointestinal illness and respiratory infections in children under 5.
The investigators will collect illness symptom data using a combination of weekly text messages and online illness questionnaires.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19122
- Temple University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 4 years (CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Child resides in Berks, Bucks, Chester, Lancaster, Lehigh, or Montgomery County in Pennsylvania
- Household is served by a private well
- Participant child is under the age of 5 (under 4 at time of enrollment), who is a full-time resident of the home and drinks untreated well water (75% or more of water consumption must be from untreated well water)
- Parent/guardian has access to a phone with texting capabilities
Exclusion Criteria:
- Child participant is immunocompromised
- Child participant has a chronic gastrointestinal condition
- Child takes daily oral steroids
- Household treats water before consumption (with the exception of water softeners)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Active UV Device
A household water treatment device with a lamp emitting germicidal UV.
The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
|
This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
|
SHAM_COMPARATOR: Inactive UV Device
A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
|
This sham device will use a lamp not emitting germicidal UV.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incident gastrointestinal illness
Time Frame: 12 months
|
The investigators will collect data on the presence of gastrointestinal illness symptoms through weekly text messages.
Households that report symptoms through text messages will be directed to an online illness questionnaire to characterize the symptoms (incidence, severity, duration, diarrhea, vomiting, coughing, etc.), febrile episodes, as well as relevant exposure information such as recent travel, exposure to ill persons, etc. Incident gastrointestinal illness (GI) is defined by the reporting of a minimum of three episodes of diarrhea or vomiting in a 24 hour period.
Each illness will be considered distinct when separated by ≥ 6 symptom-free days.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Heather Murphy, PhD, Assistant Professor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hellard ME, Sinclair MI, Harris AH, Kirk M, Fairley CK. Cost of community gastroenteritis. J Gastroenterol Hepatol. 2003 Mar;18(3):322-8. doi: 10.1046/j.1440-1746.2003.02959.x.
- Johnson TD, Belitz K, Lombard MA. Estimating domestic well locations and populations served in the contiguous U.S. for years 2000 and 2010. Sci Total Environ. 2019 Oct 15;687:1261-1273. doi: 10.1016/j.scitotenv.2019.06.036. Epub 2019 Jun 6.
- Roberts JA, Cumberland P, Sockett PN, Wheeler J, Rodrigues LC, Sethi D, Roderick PJ; Infectious Intestinal Disease Study Executive. The study of infectious intestinal disease in England: socio-economic impact. Epidemiol Infect. 2003 Feb;130(1):1-11. doi: 10.1017/s0950268802007690.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 30, 2020
Primary Completion (ACTUAL)
May 1, 2022
Study Completion (ANTICIPATED)
June 1, 2023
Study Registration Dates
First Submitted
February 3, 2020
First Submitted That Met QC Criteria
February 4, 2020
First Posted (ACTUAL)
February 6, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 2, 2022
Last Update Submitted That Met QC Criteria
July 29, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 25665 (Pilot Trial)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Viral Infection
-
SciensanoJessa Hospital; Universitair Ziekenhuis Brussel; AZ Sint-Jan AV; Centre Hospitalier... and other collaboratorsCompletedInfluenza Viral Infections | Respiratory Viral Infection | Severe Acute Respiratory Infection
-
Hospices Civils de LyonRecruiting
-
Xlear, IncMetanoic Health Ltd.Not yet recruitingRespiratory Viral Infection
-
A. Vogel AGCompletedRespiratory Tract Infection ViralSwitzerland
-
University of Wisconsin, MadisonCompletedRespiratory Viral InfectionUnited States
-
Materia Medica HoldingCompletedAcute Respiratory Viral InfectionRussian Federation
-
Materia Medica HoldingCompletedViral Respiratory InfectionRussian Federation
-
Nanjing Zenshine PharmaceuticalsNot yet recruiting
-
Thirty Respiratory LimitedWithdrawnPREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) (PREVENT)Respiratory Tract Diseases | COVID-19 Respiratory Infection | Respiratory Viral InfectionUnited Kingdom
-
Stanford UniversityCenters for Disease Control and Prevention; International Centre for Diarrhoeal...Not yet recruitingSARS-CoV2 Infection | Influenza Viral Infections | Respiratory Viral Infection
Clinical Trials on Active household UV water treatment device
-
Temple UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingDiarrhea | Respiratory Viral Infection | Gastrointestinal Infection | Waterborne DiseasesUnited States
-
London School of Hygiene and Tropical MedicineUnited States Agency for International Development (USAID); Population Services... and other collaboratorsCompleted
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
National Institute on Aging (NIA)Completed
-
Elira, Inc.Recruiting
-
Haramaya UnversityCompleted
-
Danyang Huichuang Medical Equipment Co., Ltd.First Affiliated Hospital of Chongqing Medical University; Rehabilitation Hospital...Enrolling by invitationMild to Moderate Alzheimer's DiseaseChina
-
metaMe HealthCompletedIrritable Bowel SyndromeUnited States
-
Click Therapeutics, Inc.WithdrawnSubstance Use Disorder | Drug Addiction | Tobacco Dependence | Drug Dependence | Nicotine AddictionUnited States
-
Taipei Veterans General Hospital, TaiwanNational Science Council, TaiwanCompleted